Last update Jan. 11, 2020

Buserelin Acetate

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Decapéptido de síntesis, similar a la gonadorelina, análogo de la hormona liberadora de la hormona luteinizante natural (LHRH).
Indicado en tratamientos de fecundación in vitro antes de la estimulación con gonadotropinas exógenas para estimulación ovárica.
Administración subcutánea diaria durante 15 a 21 días.
Se utiliza también en carcinoma de próstata y endometriosis.

La buserelina, administrada por inhalación intranasal, se excreta en leche materna en cantidad ínfima o indetectable y no produce alteraciones hormonales en lactantes amamantados por madres que la tomaban (Dewart 1987) ni alteraciones en la lactancia (Fraser 1989).

Su peso molecular elevado explicaría este ínfimo paso a leche materna.
Por su naturaleza proteica es inactivado en el tracto gastrointestinal (Van Leusden 1994, Fraser 1993), no absorbiéndose, (biodisponibilidad oral prácticamente nula), lo que dificulta o impide el paso a plasma del lactante a partir de la leche materna ingerida, salvo en prematuros y periodo neonatal inmediato, en los que puede haber mayor permeabilidad intestinal.

En mujeres tratadas con análogos de la gonadorelina y gonadotrofinas se ha observado aumento de prolactina (Cavagna 2005, Kamel 1994, Meldrum 1992), aunque el hallazgo no es constante (Chantilis 1995).


See below the information of these related products:

  • Assisted Reproductive Techniques (ART) (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Gonadorelin (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

We do not have alternatives for Buserelin Acetate since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Buserelin Acetate is also known as Buserelin.


Buserelin Acetate in other languages or writings:

  • بوزيريلين (Arabic)
  • Бусерелин (Cyrillic)
  • 布舍瑞林 (Chinese)
  • ブセレリン (Japanese)
  • (6-O-tert-Butyl-d-serine)-des-10-glycinamidegonadorelin ethylamide; 5-Oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-O-tert-butyl-d-seryl-l-leucyl-l-arginyl-N-ethyl-l-prolinamide (Chemical name)
  • C60 H86 N16 O13 (Molecular formula)
  • L02AE01 (ATC Code/s)

Group

Buserelin Acetate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Buserelin Acetate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.239 daltons
Protein Binding 15 %
Tmax 1 hours
T½ 1.3 hours

References

  1. AEMPS- Sanofi Aventis. Buserelina (Suprefact) Ficha técnica. 2016 Full text (in our servers)
  2. Sanofi-Aventis. Buserelin (Suprefact). Drug Summary. 2015 Full text (in our servers)
  3. Cavagna M, Mantese JC, Freitas Gda C, Dzik A, Soares JB, Hameiry Y, Izzo VM, Pinotti JA. Pattern of prolactin secretion after administration of gonadotropin-releasing hormone agonist at the preovulatory phase of intrauterine insemination cycles. Sao Paulo Med J. 2005 Nov 3;123(6):295-7. Epub 2006 Jan 20. Abstract
  4. Chantilis SJ, Barnett-Hamm C, Byrd WE, Carr BR. The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women. Fertil Steril. 1995 Oct;64(4):698-702. Abstract
  5. Van Leusden HA. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol. 1994 Sep;8(3):215-22. Review. Abstract
  6. Kamel MA, Zabel G, Bernart W, Neulen J, Breckwoldt M. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme. Hum Reprod. 1994 Oct;9(10):1803-6. Abstract
  7. Fraser HM. GnRH analogues for contraception. Br Med Bull. 1993 Jan;49(1):62-72. Review. Abstract
  8. Meldrum DR, Cedars MI, Hamilton F, Huynh D, Wisot A, Marr B. Leuprolide acetate elevates prolactin during ovarian stimulation with gonadotropins. J Assist Reprod Genet. 1992 Jun;9(3):251-3. Abstract
  9. Fraser HM, Dewart PJ, Smith SK, Cowen GM, Sandow J, McNeilly AS. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women. J Clin Endocrinol Metab. 1989 Nov;69(5):996-1002. Abstract
  10. Dewart PJ, McNeilly AS, Smith SK, Sandow J, Hillier SG, Fraser HM. LRH agonist buserelin as a post-partum contraceptive: lack of biological activity of buserelin in breast milk. Acta Endocrinol (Copenh). 1987 Feb;114(2):185-92. Abstract

Total visits

544

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM